Cost-effectiveness analysis of the first‐line EGFR‐TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer-Reference-Cited by-同舟云学术

Cost-effectiveness analysis of the first‐line EGFR‐TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer

Author:

Aguilar-Serra J¹,Gimeno-Ballester V²,Pastor-Clerigues a¹³,Milara J¹³⁴⁵,Trigo-Vicente C⁶⁷,Cortijo J¹³⁵

Affiliation:

1. Department of Pharmacology, Faculty of Medicine, University of Valencia, Valencia, Spain

2. Department of Pharmacy, Hospital Universitario Miguel Servet, Zaragoza, Spain

3. Department of Pharmacy, University General Hospital Consortium, Valencia, Spain

4. Department of Pharmacy, Research Foundation of General Hospital of Valencia, Valencia, Spain

5. CIBERES, Health Institute Carlos III, Valencia, Spain

6. Department of Pharmacy, C.r.p. Nuestra Señora Del Pilar, Zaragoza, Spain

7. Department of Pharmacy, Universidad San Jorge, Zaragoza, Spain

Funder

funded

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

Reference88 articles.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献